Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCHES enzalutamide plus ADT in metastatic hormone-sensitive prostate cancer
NL-OMON53121Phase 3Recruiting
- Sponsor
- Astellas Pharma
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Enzalutamide plus ADT with Placebo plus ADT (2 arms). Primary endpoint: Radiographic progression-free survival. Started Nov 2016; status: recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON53121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53121.